<div id="readability-page-1"><article><div>Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. Frédéric Wuilque, VP-Global Products, Volition commented :&#34;Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years.&#34;Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.&#34;We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms.&#34;The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:<ul type="disc"><li>Large Population: There are approximately 73.8 million pet cats in the United States alone3.</li><li>High Risk: It is estimated that approximately 1 in 5 cats will develop cancer in their lifetime4. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.</li><li>The &#34;Senior&#34; Segment: Over 25% of U.S. cats are considered seniors (aged 8+)5, representing a recurring annual screening opportunity for over 18 million pets in the U.S.3,5</li><li>Market Growth: The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster Compound Annual Growth Rate than the canine segment due to increasing owner awareness and a growing focus on feline-specific treatments&#34;6.</li></ul>Gael Forterre, Chief Commercial Officer, Volition commented:&#34;This represents a tremendous commercial opportunity for Volition:<ul type="disc"><li>the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment.</li><li>we will also generate ongoing revenue, in this large and growing market where our technology meets an unmet need</li></ul>&#34;The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space.&#34;<ol type="1"><li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.</li><li>Data on file, Volition</li><li>AVMA Pet Ownership Sourcebook (2025) &amp; APPA National Pet Owners Survey (2025)</li><li>Can Cats Get Cancer? Understanding Feline Cancers Like Lymphoma &amp; SCC. Imprimed</li><li>Data on file, Volition TAM model</li><li>Towards Healthcare: Veterinary Oncology Market Insights (October 2025)</li></ol>About Volition About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0) 7557 774620Investor Relations: Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568Safe Harbor StatementStatements in this press release or associated video or link may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the UnitedSOURCE VolitionRx Limited</div></article></div>

VNRX

VolitionRx Limited (NYSE AMERICAN: VNRX) has announced breakthrough clinical data for its Nu.Q® Vet Feline assay, achieving 100% specificity in detecting lymphoma in cats, with over 80% detection accuracy. This marks the potential launch of the world's first affordable blood-based liquid biopsy test for feline cancer, addressing a significant need in veterinary medicine. The North American veterinary oncology market is projected to grow, with Volition aiming to capitalize on this opportunity. The Nu.Q® Vet Canine test is already available in over 20 countries, and the feline test could double their market reach.

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats | VNRX Stock News